1.A summary of the clinical practice guidelines for the management of patients with Peripheral Arterial Disease in Myanmar
Than Than Aye ; Tint Swe Latt ; Khin Mg Lwin ; Win Win Kyaw ; Myint Soe Win ; Moe Wint Aung ; Ko Ko ; Thein Myint ; Yin Yin Win
Journal of the ASEAN Federation of Endocrine Societies 2013;28(2):114-125
Peripheral artery disease (PAD) broadly encompasses vascular diseases caused primarily by atherosclerosis and thromboembolic pathophysiologic processes that alter the normal structure and function of the aorta, its visceral arterial branches, and the arteries of the lower extremity. The aims of the Myanmar clinical practice guidelines for the management of patients with PAD are to assist physicians in selecting the best management strategies for an individual patient with peripheral artery disease with main focus on lower extremity artery disease (LEAD) due to atherosclerosis, to help the physician to make decisions in their daily practice, and to aid in appropriate referrals to specialists. Early detection and treatment guidelines for the treatment of PAD are important to reduce the morbidity and mortality of patients with vascular problems in Myanmar.
Peripheral Arterial Disease
;
Practice Guideline
;
Myanmar
2.Profile of various idiopathic inflammatory myopathies at two university hospitals in Yangon, Myanmar
Ohnmar ; Zin Phyu Tun ; Cho Cho Nyunt ; Su Lei Htay ; Soe Lin Oo ; Cho Mar Lwin ; Yin Minn Soe ; Chit Soe ; Win Min Thit
Neurology Asia 2020;25(3):285-291
Objective: to determine the distribution of various idiopathic inflammatory myopathies (IIM) and
their profile at the largest university hospitals in Yangon, Myanmar. Method: It was a hospital based
prospective study recruiting IIM patients admitted to Neurology and Rheumatology ward over a 1.5
year period from September 2017 to February 2019. Results: Among total 51 IIM patients recruited,
62.7% presented to Neurology ward and 37.3% to Rheumatology ward. Overlap myositis (OM)
was the commonest (43%), followed by immune-mediated necrotizing myopathy (IMNM) 27%,
dermatomyositis (DM) 24%, polymyositis (PM) 6%. Among OM, anti-synthetase syndrome (ASS)
was 23%, and among IMNM, anti-SRP positive was 79%. IMNM and PM patients presented more
to neurologists while OM/ASS and DM more to rheumatologists; 82% were females (F:M= 4.6:1).
Mean age of onset of myositis was 40.2 + 17.8 years, and duration of symptoms before presentation
was 10-3,600 days (shortest in anti-SRP and longest in anti-HMGCR myopathy). Myositis antibodies
were positive in 67%. CK range was 40-25,690 U/l, highest in IMNM and lowest in DM. Associated
connective tissue diseases among OM in order of descending frequency were 47% systemic lupus
erythematosus, 24% Sjogren syndrome, 41% scleroderma and 12% rheumatoid arthritis. Associated
cancer identified were one lung cancer in DM, one breast cancer in OM, one buccal cancer in IMNM
cases.
Conclusions: With recent availability of myositis antibody panel and MHC staining in Myanmar, we
have applied current updated classification to describe the first Myanmar data on IIM cases.